Detail akcie Verrica Pharma Rg online

Business Summary: Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Verrica Pharmaceuticals Inc revenues increased from $7.2M to $30.5M. Net loss decreased 84% to $9.8M. Revenues reflect License And Collaboration Revenue increase from $963K to $18.9M, Sales of Goods & Services - Net increase of 85% to $11.6M. Lower net loss reflects General and administrative - Balancing decrease of 38% to $25M (expense).